Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer.
Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published detailed results of aPhase I/II trial evaluating its lead candidate ilixadencel, which is currently in Phase II to treat metastatic renal cell carcinoma (mRCC),for which no effective treatments are available.
The experimental therapy was administered in combination with Pfizers sunitinib, approved for the treatment of RCC, and Immunicum has kept monitoring the 11 patients after officially completing the study in 2014. As of 2017, five patients are still alive and the mean overall survival has reached 48 months, which is a huge improvement when compared to the approximately 15 months expected with standard therapies.
CT scans of the brain of a patient that showed a complete disappearance of all brain and liver metastases (a) before and (b) 6 months aftercompleting the treatment
Ilixadencel, previously known as Intuvax, is composed ofactivated dendritic cellsderived from healthy donors that are injected into the tumor, where theyrecruit the patients own immune system. Its an off-the-shelf cell therapyobtained from healthy donors, which would result in easier manufacturing and lower costs as compared to patient-derived cells.
In theory, this strategy could be applied toany injectable solid tumor,whichis particularly exciting given that targetingsolid tumors is still a huge challenge. We believe that the future of cancer treatment lies in the rapidly evolving landscape of combination therapies and ilixadencel is uniquely positioned to become an integral part of modern combination regimens, saidAlex Karlsson-Parra, CSO of Immunicum, in a statement.
According to Carlos de Sousa, CEO of the company, the effort to publish the results is part of the companys strategy to communicate its data and build validation for its technology. As he commented during an oncology panel at Labiotech Refresh, the regulatory authorities in Europe are struggling to keep up with the rapid advances in the field.
Immunicum is not the only developing cell-based therapies for cancer. The French PDC*line Pharma is also focusing on dendritic cells, while many others compete to bring the promising CAR-T cell technology to the market.Ensuring the data is available is a great initiative to help build laws that will adequately regulate these novel technologies.
Images via xrender / Shutterstock;Laurell et al., Journal for ImmunoTherapy of Cancer 2017 5:52
Read the rest here:
Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer - Labiotech.eu (blog)
- Harnessing naturally occurring mutations for T-cell therapy: a potential new avenue to enhance treatment efficacy ... - Nature.com - May 3rd, 2024
- Replay wins IND clearance for PRAME T cell cancer therapy - Clinical Trials Arena - May 3rd, 2024
- Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders - OncLive - May 3rd, 2024
- Cell Therapy is Now on The Table for Metastatic Melanoma - InventUM - University of Miami - May 3rd, 2024
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th ... - PR Newswire - May 3rd, 2024
- Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb - May 3rd, 2024
- Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the ... - Yahoo Finance - May 3rd, 2024
- The potential and promise for clinical application of adoptive T cell therapy in cancer - Journal of Translational Medicine - Journal of Translational... - May 3rd, 2024
- NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML - OncLive - May 3rd, 2024
- Carbon Biosciences Announces Four Presentations at the American Society of Gene and Cell Therapy 27th Annual ... - PR Newswire - May 3rd, 2024
- CAR T-Cell Therapy Broadens Second-Line Treatment in LBCL - Targeted Oncology - May 3rd, 2024
- CAR T-Cell Therapy Market to Reach Valuation of USD 22.2 Billion By 2032: Astute Analytica - Yahoo Finance - May 3rd, 2024
- Multiply Labs and Wilson Wolf Corporation Collaborate to Automate G-Rex Bioreactor for Cell Therapy Manufacturing - Business Wire - May 3rd, 2024
- Mammoth Biosciences to Present at Annual Meeting of the American Society of Gene & Cell Therapy - Business Wire - May 3rd, 2024
- Ingenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDA - PR Newswire - May 3rd, 2024
- Cell and gene therapy companies trip at scalability hurdle - Pharmaceutical Technology - May 3rd, 2024
- Panasonic and Shinobi team on cost-effective cell therapy tech - BioProcess Insider - May 3rd, 2024
- The Future of Cell and Gene Therapy Purification - The Medicine Maker - May 3rd, 2024
- BMS closes Redwood City cell therapy research site - Fierce Biotech - May 3rd, 2024
- FDA drafts two guidances on safety testing for cell and gene therapy products - Regulatory Focus - May 3rd, 2024
- Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma - Physician's Weekly - May 3rd, 2024
- ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual ... - GlobeNewswire - May 3rd, 2024
- What Lies Ahead? Shaping the Future of Cell and Gene Therapy - Genetic Engineering & Biotechnology News - May 3rd, 2024
- AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 - GlobeNewswire - May 3rd, 2024
- Somite Therapeutics to Present at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT) - PR Newswire - May 3rd, 2024
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022